appear pois linger
low-qual ep beat overshadow
deceler top-line trend disappoint
commentari implicitli guid -msd/hsd ebitda
declin remain skeptic fundament prospect
lower pt remain ew given valuat reflect
top line challeng weigh outlook stock trade
 low-qual ep beat driven lower tax sg
overshadow deceler top-line trend disappoint outlook
importantli cut dividend manag reiter
confid balanc sheet abil pay dividend current cover
free cash flow howev still view necessari step
outweigh key neg takeaway day top-line trend
notic deceler price measur particularli chees
meat categori us driven sharp declin volum notabl total
us volum declin yoy manag give explicit
top-line guidanc us scanner trend indic volum trend remain
weak total scanner volum declin yoy end
albeit hurt snap time vs heighten
competit privat label segment privat label captur
bp us scanner market share chees bp bacon bp ground
coffe bp lunch meat initi commentari
pessimist market anticip manag give rough
indic estim near yoy declin ebitda consensu
forecast driven combin cost inflat divestiture/fx
impact meanwhil saw mln impair charg
intern busi maxwel hous brand whole visibl
remain low push full strateg review may march prior
lower estim ep price target
back weaker top-line trend margin pressur
food unit state america
unless otherwis note metric base modelwar
base consensu methodolog
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
remain ew risk-reward skew appear balanc bearish long-
term fundament outlook reflect ebitda multipl
outlook commentari give offici guidanc
stop give guidanc last year manag provid preliminari
thought confer call around outlook ebitda
affect mln headwind mln divestitur impact
higher incent compens commodities/suppli chain headwind
fx headwind mln fall mln
roughli ebitda free cash flow expect least
mln ahead dividend commit impli bln free cash flow
vs bln line item guidanc includ stock base
compens mln vs mln incom mln vs
mln effect tax rate vs
strateg commentari indic share full strateg review may
manag commentari near-term turnaround remain
line past comment cover note result see
highlight increment point mention brand-build
focu manag highli priorit flagship brand
seek better effici market spend reduc number extern
agenc total market dollar expect rise yoy work
media spend see yoy boost short manag reiter goal
fewer bigger bolder innov market initi
employe turnov concern manag key
problem area address reinforc upper
manag team current believ necessari talent execut
turnaround plan focus gener greater cog effici
support sku ration
number ep ahead consensu
estim mse cent upsid vs mse come oper
profit lower expect sg off-set weak gross margin cent
upsid come tax top-line organ sale declin vs
streetaccount consensu mse drive revenu miss
vs consensu organ sale declin punctuat declin
us notabl volume/mix declin price
highlight shipment declin notabl chees coffe cold cut bacon
respons higher price well distribut declin cold cut
frozen categori spite strong price also support
time impact lower promot intens vs gross margin declin
bp yoy albeit sequenti improv vs bp yoy came
bp consensu result gross profit miss vs consensu
howev lower expect sg level highlight lower
procurement/logist cost lower variabl compens result slight
oper profit beat vs consensu although oper margin
contract bp yoy vs bp profit line lower
expect tax rate drove cent ep upsid vs mse report
earn drag mln impair loss quarter
relat australia new zealand busi latam export busi
deriv base case scenario
growth acceler margin upsid bp top-line upsid us market
share gain int upsid drive organ sale compound-annual-growth-rate
bps/yr margin expans top-line leverag resumpt product
compound-annual-growth-rate post wacc tgr exit multipl strateg
premium consolid halo return
stabil follow expect ebitda declin
model stabil start ebitda compound-annual-growth-rate growth
outsid north america mostli off-set continu weak
wacc tgr exit multipl
top-line deceler margin pressur continu bp top-line downsid
linger us market share struggl drive organ sale
compound-annual-growth-rate margin declin bps/yr price pressur fix cost de-lever
higher reinvest drive ebitda compound-annual-growth-rate dcf input
revenue/ebitda compound-annual-growth-rate post wacc tgr exit
declin expect
easi comparison support sequenti
improv organ sale
deep dive us busi
sale highlight leverag low/no
growth end market weak competit
momentum backdrop
toward bottom peer
expans drive profit margin
unsustain level see margin
pressur linger higher
reinvest need expect
improv post see risk
wide ii advertis spend still well
histor level iii recent
margin compress
mainli driven gm compress still
leav core sg wide gap
stock price under-perform
trade ev/ebitda low growth
packag food peer k/gis/sjm/cag
believ appropri reflect bearish
risk achiev price
trend price environ increment
strateg potenti sector rotat
yoy chg sale
good sold
sale
yoy chg gp
sell gener adminstr expens
sg sale
yoy chg sg
oi sale
yoy chg oi
profit tax
yoy chg pbt
incom continu oper
incom attribut
yoy chg ni
incom attribut common
yoy chg adj ep
cash equival
s-t debt interest payabl
accumul comprehens incom loss
total liabil stockhold equiti
bridg gaap net incom
adjust reconcil net incom
depreci amort
defer compens stock compens
chang oper asset liabil effect
account payabl accru expens
net cash flow oper activ
flow invest activ
sale busi
purchas busi
net cash flow invest activ
flow financ activ
repurchas common share
issuanc common share
net cash flow financ activ
effect fx chang cash cash equival
cash equival begin year
net chang cash cash equival
cash equival end year
